Research window: 25 September–2 October 2026. Four newly published human studies offer useful evidence on deficiency treatment, clinical nutrition, frailty and cognition. None establishes that a supplement extends human lifespan. This is a research update, not a comprehensive supplement review or an A–F evidence grade.
1. Zinc: correcting deficiency is different from general immune boosting
Published 30 September 2026. A double-blind, 12-month randomised trial enrolled 105 zinc-deficient nursing-home residents; 84 completed it. By month eight, all remaining participants receiving 60 mg/day elemental zinc reached the study’s adequacy threshold, compared with 46% receiving 30 mg/day and none receiving the control supplement.
Why it matters: This adds direct dose-comparison evidence in deficient older adults. It does not establish pneumonia prevention: the trial was not powered for that clinical outcome. All capsules contained copper; unchanged serum copper is not proof of unrestricted long-term safety.
Practical interpretation: The findings inform supervised deficiency treatment, not routine high-dose use in healthy people. NIH-funded, with no commercial conflicts declared. Worth reading in full: yes, especially the dosing and safety limitations. Read the zinc trial.
2. Protein: better laboratory markers do not necessarily mean better outcomes
Published 25 September 2026. A systematic review and meta-analysis of 33 randomised trials involving 11,622 critically ill patients found no mortality benefit from higher protein provision: risk ratio 1.02 (95% confidence interval 0.97–1.08). Some muscle and biochemical measures improved without an overall improvement in clinical outcomes.
Why it matters: This updated synthesis highlights meaningful null results. An acute kidney injury subgroup showed higher mortality with higher protein provision (risk ratio 1.46), although subgroup findings require cautious interpretation.
Practical interpretation: Protein targets during critical illness need individual clinical assessment. This is not evidence about protein powder or optimal intake for healthy adults doing resistance training. Public foundation funding; no commercial conflicts declared. Worth reading in full: yes, for the null results, bias assessment and renal safety signal. Read the protein meta-analysis.
3. Pectin and frailty: an interesting pilot, not a treatment recommendation
Published 28 September 2026. A four-week, double-blind pilot trial enrolled 31 older adults with frailty; 29 completed it. Adding 10 g/day low-methoxy pectin improved sit-to-stand repetitions by about 2.1 versus 0.7 with the comparator. Timed Up and Go and circulating inflammatory markers did not improve significantly.
Why it matters: This brings preliminary human functional evidence to an area previously supported largely by mechanistic research. However, the primary inflammatory outcomes were null. Positive functional and psychological findings were secondary, with multiple comparisons and short follow-up.
Practical interpretation: Too early to recommend pectin for frailty. NIHR-funded; no commercial role in the study reported, although some authors disclosed outside industry relationships. Worth reading in full: optional, particularly to compare the headline with the primary results. Read the pectin trial.
4. Blackcurrant formulation: a narrow cognition signal
Published 30 September 2026. A small double-blind crossover trial reported 26 per-protocol completers. Four weeks of a blackcurrant, L-theanine and pine-bark formulation reduced false alarms on an attention task. The fatigue result did not meet the conventional threshold after multiplicity adjustment (q = 0.067).
Why it matters: These are new cognitive results from a cohort whose sleep findings were previously published, not an independent replication. Peripheral biochemical changes do not establish brain protection or slower ageing.
Practical interpretation: The study does not demonstrate dementia prevention, lifespan extension or a benefit attributable to blackcurrant alone. Industry co-funding and an author’s company and patent ties are relevant. Worth reading in full: if assessing this particular formulation or its marketing claims. Read the cognition trial.
Free · every Friday
Get the Evidence Update in your inbox
Each week: the new human studies worth knowing about, what they actually show — and what they don’t. Written by a pharmacist. No sponsors, no product promotions, unsubscribe any time. See our Privacy Policy.
Educational research summary. Individual study findings should be interpreted alongside the wider evidence base and the population actually studied. Last updated: 2 October 2026.